Correlation Between 09247XAS0 and Spyre Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 09247XAS0 and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 09247XAS0 and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between BLK 21 25 FEB 32 and Spyre Therapeutics, you can compare the effects of market volatilities on 09247XAS0 and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 09247XAS0 with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 09247XAS0 and Spyre Therapeutics.

Diversification Opportunities for 09247XAS0 and Spyre Therapeutics

-0.35
  Correlation Coefficient

Very good diversification

The 3 months correlation between 09247XAS0 and Spyre is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding BLK 21 25 FEB 32 and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and 09247XAS0 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BLK 21 25 FEB 32 are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of 09247XAS0 i.e., 09247XAS0 and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between 09247XAS0 and Spyre Therapeutics

Assuming the 90 days trading horizon 09247XAS0 is expected to generate 391.68 times less return on investment than Spyre Therapeutics. But when comparing it to its historical volatility, BLK 21 25 FEB 32 is 20.72 times less risky than Spyre Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  975.00  in Spyre Therapeutics on September 3, 2024 and sell it today you would earn a total of  1,868  from holding Spyre Therapeutics or generate 191.59% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy96.16%
ValuesDaily Returns

BLK 21 25 FEB 32  vs.  Spyre Therapeutics

 Performance 
       Timeline  
BLK 21 25 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BLK 21 25 FEB 32 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 09247XAS0 is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Spyre Therapeutics 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Spyre Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Spyre Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

09247XAS0 and Spyre Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 09247XAS0 and Spyre Therapeutics

The main advantage of trading using opposite 09247XAS0 and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 09247XAS0 position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.
09247XAS0 vs. Spyre Therapeutics
09247XAS0 vs. BBB Foods
09247XAS0 vs. FitLife Brands, Common
09247XAS0 vs. Chimerix
The idea behind BLK 21 25 FEB 32 and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Spyre Therapeutics vs. DiaMedica Therapeutics
Spyre Therapeutics vs. Lyra Therapeutics
Spyre Therapeutics vs. Centessa Pharmaceuticals PLC
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY